The aim of this review was to discuss the most recent data from current trials of diethylstilboestrol (DES) to identify its present role in advanced prostate cancer treatment as new hormonal therapies emerge.
The most relevant clinical studies using DES in castration-refractory prostate cancer (CRPC) were identified from the literature. The safety, efficacy, outcomes and mechanisms of action are summarized. In the age of chemotherapy this review highlights the efficacy of oestrogen therapy in CRPC. The optimal point in the therapeutic pathway at which DES should be prescribed remains to be established.
Written by:
Turo R, Smolski M, Esler R, Kujawa ML, Bromage SJ, Oakley N, Adeyoju A, Brown SC, Brough R, Sinclair A, Collins GN. Are you the author?
Department of Urology, Stepping Hill Hospital, Stockport NHS Foundation Trust, Stockport, UK.
Reference: Scand J Urol. 2013 Nov 21. Epub ahead of print.
doi: 10.3109/21681805.2013.861508
PubMed Abstract
PMID: 24256023
UroToday.com Prostate Cancer Section
